THE European Commission has approved Sandoz' rituximab biosimilar Rixathon (also approved as Riximyo), for treatment of blood cancers and immunological diseases, according to an announcement from Sandoz' parent company Novartis.
The reference product is Roche's MabThera which will consequently be under pricing pressure.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Jun 17